arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

BIOMERICA INC

BMRA
$1.60 ▼ -0.04 (-2.44%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
63 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
13
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOMERICA INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.8M
Dividend Yield
Revenue Growth -11.8%
Op. Margin -131.5%
ROIC -39.4%
FCF / Share $-0.42
Trailing P/E
Price / Book 1.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

63-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$987.00K
↓ -11.8%
Net Income Profit after all expenses
$2.00K
— 0.0%
Operating Margin Operating profit as % of sales
-131.5%
↓ -15.9% 2th
FCF / Share Free cash flow per share
$-0.42
↓ -21.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
7
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 63 quarters